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Dual mTOR/PI3K inhibition 
limits PI3K-dependent pathways 
activated upon mTOR inhibition 
in autosomal dominant polycystic 
kidney disease
Yang Liu1,10, Martin Pejchinovski2, Xueqi Wang3, Xuebin Fu4, Deborah Castelletti5,  
Terry J. Watnick6, Alexandre Arcaro7, Justyna Siwy2, William Mullen8, Harald Mischak2,8 & 
Andreas L. Serra9
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney 
cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) 
slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials 
failed to prove efficacy of mTOR inhibitor treatment. Here, we demonstrate that treatment with 
mTOR inhibitors result in the removal of negative feedback loops and up-regulates pro-proliferative 
phosphatidylinositol 3-kinase (PI3K)-Akt and PI3K-extracellular signal-regulated kinase (ERK) signaling 
in rat and mouse PKD models. Dual mTOR/PI3K inhibition with NVP-BEZ235 abrogated these pro-
proliferative signals and normalized kidney morphology and function by blocking proliferation and 
fibrosis. Our findings suggest that multi-target PI3K/mTOR inhibition may represent a potential 
treatment for ADPKD.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially lethal monogenetic 
hereditary kidney disease. It is characterized by progressive dilation of renal tubules that eventually form cysts, 
leading to kidney failure1. The loss of the major function of the kidneys due to cysts expansion has been largely 
associated with unexpected or asymptomatic well-know germ-line mutations, somatic mutations or even by rep-
erfusion processes of ischemic tissue. These adverse effects are followed by glomerular hyperfiltration as a result 
of excess fluid accumulation1,2.
One of the key components is the mammalian target of rapamycin (mTOR) kinase which is a master regulator 
of protein synthesis and proliferation aberrantly activated during ADPKD onset2,3. Although treatment with 
mTOR inhibitors has shown positive results in preventing massive renal enlargement in a variety of polycystic 
kidney disease (PKD) animal models, clinical trials have not been able to show the same beneficial effect of 
mTOR inhibitors treatment in ADPKD patients4–8. It could be argued that a lack of good experimental study 
design, inappropriate drug dosage, inadequate therapy duration or patient stratification could be the reasons 
for such poor clinical outcomes. However, several studies investigated the dual negative feedback loop in a vari-
ety of human cancers: mTOR/S6K activation attenuates upstream phosphatidylinositol 3-kinase (PI3K) pathway 
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activation, while treatment with mTOR inhibitors (rapamycin and its analogs) lead to a hyperactive insulin 
receptor substrate 1 (IRS-1)/PI3K pathway. This, in turn, increases the signaling toward the pro-proliferative 
extracellular signal-regulated kinases (ERK) and Akt pathways9–12. Based on these findings and our previous 
experimental work, we hypothesized that mTOR inhibition might also lead to compensatory up-regulation of 
the PI3K-dependent pathway in ADPKD by the release of mTOR controlled negative feedback loops that may 
attenuate the efficacy of mTOR inhibitors.
Results and Discussion
To explore our hypothesis we examined the effect of mTOR inhibitors on these dual negative feedback loops in 
vitro and in an animal model of PKD. For this purpose, we first treated Han:SPRD male rats, a well characterized 
strain (Cy/+) that resembles human ADPKD, with the rapamycin analog everolimus (gavage 3 mg/kg/day) from 
4 to 16 weeks of age8,13,14. As a result, treatment with everolimus increased the activity of readouts of PI3K/Akt 
and PI3K/ERK in the polycystic kidney (Fig. 1A). Phosphorylation of T202/204-ERK, T308-Akt and S473-Akt 
were increased in polycystic kidneys of Cy/+ animals whereas in wild type animals these pathways were not 
activated by everolimus. In our next in vitro analysis, cultured Han:SPRD Cy/+ male renal tubular epithelial 
cells (TEC) were further investigated by everolimus treatment. This resulted in increased Akt and ERK activation 
and decreased activity of mTOR (phosphorylation of T389-S6K, T421/S424-S6K, S235/236-S6 and S240/244-S6, 
respectively) when used in a dose-dependent manner (Fig. 1B and D).
Previously although applying different methodology, Belibi and her colleagues carried out a similar study 
to determine the effect of rapamycin on PKD and the influence of the drug evaluation throughout alternation 
of pro-proliferative mammalian target of rapamycin complexes (mTORC1 and mTORC2) in female Han:SPRD 
cystic rats. The authors reported an increased S473-Akt in female Cy/+ after 9 weeks of ip injections of 0.2 mg/kg 
rapamycin per day. Interestingly, the opposite effect was observed when the same approach was applied in male 
Cy/+ rats, decreasing the S473-Akt activity suggesting a dose-dependent alteration of the S473-Akt regulation. 
Furthermore, differences in drug application method and treatment duration (gavage, 5 weeks treatment versus 
Figure 1. Mammalian TOR pathway blockage triggered dual PI3K-dependent feedback loops stemming from 
S6K to PI3K/ERK and to PI3K/Akt in PKD. (A) Han:SPRD rats whole kidney lysates western blot analysis 
and densitometry of PI3K/Akt and PI3K/ERK pathway readouts after 12 weeks everolimus (E) or vehicle 
(V) treatment (n = 4 per group). **p < 0.01 indicated by brackets. (B) mTOR upon treatment with indicated 
everolimus concentration for 48 h. (C) Cell viability (MTS, left panel) and DNA synthesis (BrdU, right panel) 
of Cy/ + renal primary tubular epithelial cells (TEC) after combined application of mTOR (everolimus, E), Akt 
(UO126, U) and ERK (perifosine, P) inhibitors for 48 h. #p < 0.001 compared to control, except where indicated 
by brackets. (D) Western blot analysis of mTOR, PI3K/Akt and PI3K/ERK pathways after 48 h combination 
treatment with the indicated inhibitors in Cy/ + TEC. Graphs are representative of three independent 
experiments. These are cropped gels and the original gels are presented in Supplementary Fig. 6.
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ip injection, 9 weeks treatment) may affect fibrosis and Akt expression levels15–17. Our in vitro and animal data 
highlighted the importance of mTOR inhibitors in assessing the effect on pro-proliferative signaling pathways in 
cystic pre-clinical animal models.
Currently, it is well-known that ADPKD is characterized by complex molecular interactions that contrib-
ute to cyst formations and further disease progression18. Often, due to the lack of appropriate translatability 
between humans and animal models, there are only a few pathological aspects that can be captured19. For this 
reason the initial PKD-associated signaling pathways were further investigated in ADPKD patients enrolled in 
the SUISSE ADPKD study5. While polycystic kidney specimens were not available from this trial, peripheral 
blood mononuclear cells (PBMCs) were isolated from patients before and after treatment with either sirolimus 
or standard care for 6 months20–22. Among sirolimus treated patients phosphorylation of ribosomal S6 protein 
was blocked whereas ERK phosphorylation was markedly increased and phospho-Akt was increased in 2 out of 
the total of 3 sirolimus treated ADPKD patients (Supplementary Fig. 1). Analysis and interpretation of our labo-
ratory data suggested similar effects of mTOR inhibition on pro-proliferative signaling in humans with ADPKD. 
Therefore, we further investigated the impact of mTOR signaling pathway upon treatment with mTOR inhibitors 
in Han:SPRD Cy/+ male renal tubular epithelial cells21. The set of everolimus, UO126, and perifosine inhibitors 
provoked triple inhibition of mTOR, ERK and Akt and in the same time considerably more effective loss of cell 
viability and inhibition of DNA synthesis than any double drug combination (Fig. 1C). Western blot analysis 
confirmed the effect of each inhibitor on the respective pathways (Fig. 1D).
The suspension of abnormal cyst proliferation and expansion in vivo was investigated by administration of 
NVP-BEZ235 treatment, a dual mTOR/PI3K inhibitor with proven efficacy in various human cancer models23–25. 
In this analysis, we administrated low-dose (15 mg/kg/day, named N-low group) and high-dose (50 mg/kg/day, 
named N-high) NVP-BEZ235 to Han:SPRD male rats between 4 and 9 weeks of age (Fig. 2A). Although this 
treatment reduced the body weight gain, in particular at the higher dose regimen, it had a dramatically positive 
effect on all aspects of the PKD disease burden: the kidney morphology (evaluated as the two kidneys weight/total 
body weight ratio, cyst volume, parenchymal fibrosis, and cell proliferation) was similar in NVP-BEZ235-treated 
PKD and in wild type animals (Fig. 2B,C Supplementary Fig. 4A–D and Supplementary Tables 1,2). In addition, 
renal function (blood urea nitrogen, serum creatinine concentration, urine albumin/creatinine ratio and plasma 
concertation) were all similar to that recorded in wild type animals (Fig. 2D–F and Supplementary Tables 1,2,7). 
We assessed the urinary proteomic/peptidomic molecular changes in the Han:SPRD rats to explore a potential 
Figure 2. Efficacy of NVP-BEZ235 treatment on Han:SPRD rats renal function. (A) Study design scheme. 
Dose-dependent effect of NVP-BEZ235 on PKD progression. (B) Representative PAS stained kidney sections 
of NVP-BEZ235-treated and vehicle-treated Han:SPRD rats. Quantitative analysis of (C) two kidneys to total 
body weight ratio (2 K/TBW), (D) 24 h urine albumin to creatinine ratio, (E) BUN, (F) serum creatinine in 
Han:SPRD rats are displayed. (G) Western blot analysis of Han:SPRD whole kidney lysates for readouts of 
mTOR, PI3K/Akt and PI3K/ERK pathways after 5 weeks treatment with NVP-BEZ235-treated and vehicle-
treated rat. Representative results of three independent experiments are shown. These are cropped gels and 
the original gels are presented in Supplementary Fig. 6. *p < 0.05, **p < 0.01, #p < 0.001 indicated by brackets 
(mean ± SD, ANOVA). The number of rat per group is indicated in Supplementary Tables 1 and 2.
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biomarker associated with the beneficial effect of the NVP-BEZ235 treatment26. (Supplementary Figure S6 and 
Supplementary Table 3). None of the animals died during the study and we observed a similar effect on body 
weight as reported for other mTORC1 inhibitors8,27. Notably, the renal function after 5 weeks of treatment was 
better in NVP-BEZ235-treated animals compared to everolimus-treated ones (Supplementary Table 4)8.
We elucidated the NVP-BEZ235 mode of action by analyzing the mTOR and its dual feedback loop pathway 
in vivo. NVP-BEZ235 blocked the mTOR pathway, as shown by the decrease of phospho-T421/S424-S6K and 
phospho-S235/236-S6. Expression of phospho-T308-Akt, phospho-S473-Akt and phospho-T202/204-ERK, used 
to monitor activation of the dual feedback loop, was prevented by the high-dose regimen, whereas the low-dose 
regimen was already sufficient to reduce the levels of phospho-S473-Akt and phospho-T202/204-ERK (Fig. 2G 
and Supplementary Fig. 3A). Kidney tissue sections of untreated-Cy/ + rats showed that cysts-lining epithelial 
cells stained strongly positive for phospho-T202/204-ERK and phospho-S235/236-S6 in the cortex and in the cor-
ticomedullary region, whereas wild type and NVP-BEZ235-treated animals displayed only a mild and scattered 
positive staining (Supplementary Fig. 4A). NVP-BEZ235 activates ERK in some cancer cells28 whereas we did not 
observe an ERK activation in our polycystic kidney models, nor in primary renal tubular epithelial cells (Fig. 2G 
and Supplementary Fig. 3B)25,29,30 Thus, dual mTOR/PI3K inhibition abrogates the up-regulation of Akt and ERK 
signaling pathways. Of note, NVP-BEZ235 had no effect on the pro-proliferative pathways, when analyzed in wild 
type treated kidneys, suggesting that the mode of action is specific for ADPKD (Fig. 2L).
To further assess the relevance of dual mTOR and PI3K-dependent pathway inhibition as a therapy for PKD, 
we compared the efficacy of NVP-BEZ235 and sirolimus in an orthologous ADPKD mouse model with a condi-
tionally inactivated Pkd1 gene31. Firstly, we induced cystogenesis by tamoxifen intraperitoneal (ip) injection into 
pups at postnatal day 11, then deterioration of the kidney function occurred over 4 to 6 weeks32. We assessed the 
efficacy of NVP-BEZ235 for two different treatment initiation time points: At an early disease state with 6 mg/kg 
dosage before weaning between day 12 and day 35 and at the same time points with 9 mg/kg after weaning (N+ 
group). Over the same time period, sirolimus with 3 mg/kg dosage (S+ group) was also applied. The late disease 
stage drug administration was evaluated between day 21 and 35 with the ip method of injection and dosage 
of 9 mg/kg NVP-BEZ235 (LN+ group) (Fig. 3A). Our preclinical results showed a marked beneficial effect at 
early disease stage mirrored by reducing kidney volume and preserving further cysts enlargement (Fig. 3B,C). 
Furthermore early treatment preserved body weight (Supplementary Fig. 3C); prevented kidney function decline 
Figure 3. Efficacy of NVP-BEZ235 and sirolimus treatment in Pkd1 conditional knockout mice. (A) Study 
design scheme. (B) Representative PAS stained kidney sections of NVP-BEZ235-treated, sirolimus-treated  
and vehicle-treated mice. Quantitative analysis of (C) two kidneys to total body weight ratio (2 K/TBW),  
(D) BUN, (E) serum creatinine, *p < 0.05, **p < 0.01, #p < 0.001 indicated by brackets (mean ± SD, ANOVA). 
The number of mice per group is indicated in Supplementary Tables 4 and 5. (F) Whole kidney lysates Western 
blot analysis of mTOR, PI3K/Akt and PI3K/ERK pathways (G) Schematic representation of the pathways 
examined in the study. mTOR pathway is abnormally activated in polycystic kidneys (left panel). Treatment 
with mTOR inhibitor results in a hyperactive PI3K-dependent pathway, increasing the signal toward the 
PI3K/Akt and PI3K/ERK pathway (middle panel). Dual mTOR/PI3K inhibitor NVP-BEZ235 may provide 
a therapeutic benefit for ADPKD by abrogating the activation of PI3K/Akt and PI3K/ERK pathways and in 
turn block the mTOR pathway (right panel). Red denotes activated; blue, inhibited. These are cropped gels and 
original gels are presented in the Supplementary Fig. 6.
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(blood urea nitrogen levels (Fig. 3D) and serum creatinine levels (Fig. E)): inhibited cytogenesis (Supplementary 
Fig. 5B), fibrogenesis (Supplementary Fig. 5C) and cell proliferation (Supplementary Fig. 5D). Sirolimus (S+ 
group) was less efficient than NVP-BEZ235 (N+ group) with respect to cystogenesis, renal function and pro-
liferation (Fig. 3B–E and Supplementary Fig. 5B–D). Western blot analysis displayed reduced expression of 
phospho-S6K, phospho-S6 and phospho-4EBP and no up-regulation phospho-ERK and phospho-Akt during 
early stage PKD (N+ group) whereas sirolimus (S+ group) triggered Akt activation (Fig. 3F and Supplementary 
Fig. 3). Late NVP-BEZ235-treated mice (LN+ group) exhibited renal function decline among all three treatment 
groups (Fig. 3B–E), and Western blot analysis indicated increased gene expression of phospho-T202/204-ERK, 
phospho-T421/S424-S6K, and phospho-S235/236-S6 (Supplementary Fig. 5A and Supplementary Tables 5,6).
Ren and his colleagues investigated safety and efficacy of NVP-BEZ235 in PCK rats, an established autosomal 
recessive polycystic kidney (ARPKD) model. The NVP-BEZ235 had no beneficial effect on cystogenesis in the 
ARPKD rodent model33. In another study, Pollizi and the colleagues have shown that NVP-BEZ235 and everoli-
mus had equivalent effects in suppressing the development of cystadenomas in a TSC2 mouse model34. In clinical 
practice, assessment of safety and efficiency of NVP-BEZ235 in 20 patients with locally advance or metastatic 
translation cell carcinoma (TCC) after failure of platinum-based therapy showed only moderate beneficial effect 
and severe drug-related complications in the majority of the patients35. We assume that even greater toxicity 
would be observed in humans required for ADPKD given the longer term dosing. Therefore, careful risk strati-
fication is of outmost importance to identify patients eligible for treatments to balance therapeutic efficacy and 
possible adverse effects.
Our signaling pathway analysis after NVP-BEZ235 treatment suggests a feedback loop. Indeed, a recent 
study has demonstrated that there is a new feedback loop compensatory activation of Rictor and S473-Akt via 
FoxO-mediated upregulation after NVP-BEZ235 treatment which can be used as a novel therapeutic target in 
human renal carcinoma cells36. Another study has shown that NVP-BEZ235 is a potential inhibitor of ataxia 
telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK), which are unexplored but may 
implicate the DNA double strand break (DNA-DSB) repair pathways in PKD37–39.
Our findings that sirolimus treatment increased renal S473-Akt level in the orthologous ADPKD mouse 
model was not observed in the study of Shillingford and colleagues. The difference could be associated with the 
PKD1cond/cond:NestinCre mice used by Shillingford. In this mouse model renal cysts arise predominantly from 
the collecting duct and distal tubules whereas in our PKD1cond/cond:Tamoxifen-Cre+ mice cysts develop in all 
nephron segments and renal dysfunction occurs over 4 to 6 weeks. Future experimental studies using a slow pro-
gressive disease model and PKD1cond/cond:NestinCre model is needed to further elucidate the effect of NVP-BEZ235 
on the signaling pathway associated with cystogenesis and cyst progression6,32.
Our study has to be interpreted in the context of the study design. Firstly, the experiments in the animal mod-
els are performed in relatively small group sizes. Secondly, only males were used for the Han:SPRD rats due to 
the different rate of disease progression in male and female rats. Thirdly, the effect of NVP-BEZ235 at high doses 
on the body weight of Han:SPRD rat suggests toxicity and thus warrants careful consideration before applying 
this drug in clinical trials. Our pre-clinical data indicated the beneficial effect of the dual mTOR/PI3K inhibitor 
NVP-BEZ235 and highlighted the need for well-designed clinical trials to explore NVP-BEZ235 as a potential 
treatment in ADPKD patients.
Conclusion
In conclusion, blockage of the mTOR pathway, by using mTOR inhibitors, triggers up-regulation of 
pro-proliferative PI3K-dependent pathways, either through the PI3K/Akt or PI3K/ERK pathway in PKD. Dual 
mTOR/PI3K inhibition specifically prevents the activation of these feedback loops and (Fig. 3G), when applied in 
early stage disease, this treatment normalizes the renal function and the morphology of ADPKD non-orthologous 
rat and orthologous mice models.
Methods
The protocols and methods used in this study were in accordance with the EU Directive 2010/63/EU-On the 
protection of animal for experimental and other scientific purposes. All standards, international convention and 
declaration were supervised by the European Group on Ethics and Protection of Animals.
Experimental animals and study design. Han:SPRD rat. The Han:SPRD rat colony was established 
in our animal facility from a litter, which was obtained from the Rat Resource and Research Center (Columbia, 
MO). Heterozygous cystic (Cy/+) and wild-type (+/+) male rats were used in this study. Figure 2A display the 
rat study set up: we applied by gavage NVP-BEZ235 (Novartis) at low-dose (15 mg/kg/day), high-dose (50 mg/kg/
day) and vehicle solution (90% PEG300 and 10% 1-mehtyl-2-pyrrolidinone, Sigma-Aldrich) from 4 to 9 weeks of 
age. Blood was collected at 4, 6.5 and 9 weeks of age for determination of serum creatinine and BUN levels. 24 h 
urine samples were collected in metabolic cages one day before the rats were killed. We applied by gavage everoli-
mus (E, 3 mg/kg/day) and vehicle solution (V) from 4 to 16 weeks of age. Rats were anesthetized with isoflurane 
and kidneys were harvested for further analysis.
Pkd1 conditional knockout mouse. Professor G.G Germino supplied the Pkd1 conditional knockout mouse. We
induced Cre recombinase activity by intraperitoneal injection of tamoxifen (1.25 mg/10 g, dissolved in corn 
oil (Sigma-Aldrich) at day 11 of age into pups. Figure 3A display the mice study set up: The mice were randomly 
allocated to seven groups; Pkd1cond/cond, Cre + vehicle (V+), Pkd1cond/cond, Cre+ early-phase NVP-BEZ235 
(N+), Pkd1cond/cond, Cre+ late-phase NVP-BEZ235 (LN+), Pkd1cond/cond, Cre+ early-phase sirolimus (S+), 
Pkd1cond/cond, Cre- vehicle (V−), Pkd1cond/cond, Cre- early-phase NVPBEZ235(N−), and Pkd1cond/cond, 
Cre- early-phase sirolimus (S−). For the N+ and Ngroups, animals were treated with 6 mg/kg/day NVP-BEZ23 
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from day 12 to day 20, and later with 9 mg/kg/day until day 35. For the S+ and S− groups, 3 mg/kg/day sirolimus 
was administrated from day 12 to day 35. For the LN+ group, mice were
treated with 9 mg/kg/day NVP-BEZ235 from day 21 to day 35. NVP-BEZ235, sirolimus and vehicle solutions 
were administrated by intraperitoneal injections. 24 h urine samples were collected by metabolic cage at day 35. 
Mice were anesthetized with isoflurane at day 36, and blood was obtained by cardiac puncture for determination 
of serum creatinine and BUN levels and kidneys were harvested for further analysis.
Biochemical analysis. Rat and mice serum creatinine and BUN levels were detected with UniCel® DxC 800 
Synchron® Clinical (Zurich Integrative Rodent Physiology). The GenWay Albumin Elisa Kits for rat were used 
for rat urine albumin concentration measurement, according to the manufacturer’s protocol.
Proteomic analysis. PKD rat urine aliquots were thawed immediately before use and 150 μl were mixed 
with 150 μl solution containing 2 M urea, 10 mM NH4OH and 0,02% SDS. Subsequently, aliquots were filtered 
with Centrisart ultracentrifugation filters (20 kDa MWCO, Sartorius, Goettingen, Germany) to remove the higher 
molecular weight proteins. Obtained filtrate was desalted using a NAP 5 gel filtration column (GE Healthcare Bio 
Science, Uppsala, Sweden) to remove urea and electrolytes. Samples were lyophilized and stored on 4 0 C. Shortly 
before CE-MS analysis, the aliquots were re-suspended in 10 μl HPLC grade H2O. CE-MS technology was per-
formed using P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Fullerton, CA), on-line couple 
to a Micro-TOF MS (Bruker Daltonic, Bremen, Germany). Spectra were accumulated every 3 s over m/z range 
of 350–3000 Da. Details of the CE-MS technology has been described previously40. Proteomic data was further 
processed by MosaVisu software package in order to deconvolve mass spectral ion peaks representing identical 
molecules at different charge states into single masses. Normalization of migration time and ion signal intensity 
(amplitude) was achieved by using internal endogenous peptide standards for biomarker quantification. Based 
on this approach using “housekeeping” peptides, calculation of the relative abundance allows both correction 
of analytical variance and correction for different dilution levels of individual urine samples. All detected poly-
peptides, characterized by their molecular mass (kDa), CE-migration time (min) and ion signal intensity, were 
matched and annotated by usage of Microsoft SQL database. Peptide marker panel was established using support 
vector machine (SVM)-based MosaCluster software package41. The reported p-values of the identified potential 
peptide markers were calculated with Wilcoxon Rank Sum test followed by adjustment of multiple testing with 
the method described by Benjamini and Hochberg42. Peptides detected with frequency of ≥90% in at least one of 
the animal groups were considered for statistical analysis.
To obtain sequence informations, urine samples were analyzed on a Dionex Ultimate 3000 RSLS nano flow 
system (Dionex, Camberly UK) couple to an Orbitrap Velos FTMS (Thermo Fisher, Bremen, Germany). The frag-
mentation method was HCD at 35% collision energy. FTMS analyzer was selected with 60 000 resolution for MS1 
and 7500 resolution for MS2. Peptides and proteins were searched against UniProt rat database and identified with 
SEQUEST spectral algorithm (Thermo), without any enzyme specificity. Precursor mass tolerance and fragment 
mass tolerance were 10 ppm and 0.05 Da, respectively. No fixed modification was selected and oxidation of methio-
nine and proline were set up as variable modifications. High confidence peptides with Xcorr ≥1.9 and rank 1 were 
accepted as most valid for identification of the peptide markers43. Mass deviation was set below ±80 ppm.
Statistics. Data are presented as mean ± SD. Statistical differences between treatment groups were performed 
by the unpaired two-tailed t-test using GraphPad Prism version 4.0 (GraphPad). P < 0.05 was considered to be 
statistically significant.
Study approval. The study was approved and ruled under animal license number 22/2010 obtained from 
Zürich Veterinary Office.
Availability of data and materials. The raw datasets used and/or analyzed during the current study are 
available from the corresponding author on reasonable request.
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